“GHOSTWRITTEN” articles commissioned by drug company Wyeth may have led to hormone replacement therapy (HRT) being recommended to healthy menopausal women, despite evidence that it increases the risk of breast cancer.
So says Adriane Fugh-Berman of Georgetown University in Washington DC, an expert witness for thousands of women with breast cancer who are suing Pfizer – which acquired Wyeth in 2009 – for damages. She analysed 1500 documents made public through litigation and found controversial statements about the HRT Prempro in dozens of peer-reviewed articles drafted for Wyeth by communications firms. The articles were published under the names of…
